Keegan Resources Inc. (AMEX:KGN) is pleased to announce the latest assay results from its Esaase Project drilling program in southwest Ghana. Keegan has encountered significant gold intercepts (greater than 10 g/t meter grade) in four different areas, 1) down dip extensions of the current resource (KEDD872, 33.2 m @ 2.31 g/t Au and KEDD878, 176.9 m @ 1.2 g/t Au), 2) the D-1 Abuabo zone (KERC885, 32 m @ 1.66 g/t Au) 3), a step out hole on the of the D structure 2 km south of existing mineralization (KERC890, 6 meters of 11.42 g/t Au and 4) a newly discovered structure located between the D structure and the main zone (KERC 897, 11 meters of 1.44 g/t Au).Keegan is a junior gold company offering investors the opportunity to share ownership in the rapid exploration and development of high quality pure gold assets. The Company is focused on its wholly owned flagship Esaase project (2.28 Moz indicated resources with an average grade of 1.2 g/t Au at a 0.4 g/t Au cutoff and 1.65 million ounces in an inferred category at an average grade of 1.2 g/t Au applying a 0.4 g/t Au cut-off for a total inferred and indicated resource of 3.93 Moz) as well as its Asumura gold project, both of which are located in Ghana, West Africa, a highly favorable and prospective jurisdiction.
Quaterra Resources Inc. (AMEX:QMM) announced it has signed an earn-in agreement with Freeport-McMoRan Mineral Properties Inc. of Phoenix, Arizona, in respect of the Company's Cave Peak, Texas, molybdenum project. In the terms of the agreement, FMMP has the exclusive right and option to acquire a 70% ownership interest in the Cave Peak project by paying 2011 land holding costs on behalf of the Company and by subsequently spending US$5 million on exploration over four years ending in 2015. Except for the 2011 land holding costs, which are a firm commitment, all other exploration expenditures are optional.
Quaterra Resources Inc. is a junior exploration company focused on making significant mineral discoveries in North America. The Company uses in-house expertise and its extensive network of consultants, prospectors and industry contacts to identify, acquire and evaluate prospects in mining-friendly jurisdictions with the potential to host large and/or high grade base metal, precious metal or uranium deposits.
Power3 Medical Products, Inc. (OTC:PWRM)
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). PWRM applies proprietary methodologies to discover and identify protein biomarkers associated with diseases.
PWRM has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. PWRM has also filed several patent applications that are currently pending for its NuroPro technology. To date, PWRM has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China. PWRM has also published 6 articles on NuroPro in peer-reviewed scientific journals. PWRM intends to publish these latest findings as well.
To learn more about PWRM visit: http://www.Power3Medical.com
HQ Sustainable Maritime Industries, Inc. (AMEX:HQS) reported financial results for the third quarter ended September 30, 2010.For the third quarter of 2010, sales increased 27% to $28.2 million, compared to $22.2 million for the third quarter of the prior year. The increase in sales was primarily the result of strength from the new feed products added in late 2009.
Aquaculture product segment sales decreased by 4% to $13.4 million, compared to $14.0 million in the third quarter of 2009. The aquaculture product segment sales decrease is primarily related to an overall volume reduction of shrimp and ocean caught fish products sold in third quarter of 2010 compared to the third quarter of 2009, slightly offset by an increase in tilapia sales.
Hiru Corporation (OTCPK:HIRU)
Shaungshi AHP has recently launched the Jiangxi Shaungshi Biological Medicines Institute:
HIRU’s subsidiary Shuangshi AHP is currently researching several new veterinary drugs for development within the next two years. HIRU launched this new institute to strengthen and speed up the research and development processes. The Institute will allow the company a better focus and concentration of its talent in bio-tech development and research.
The company intends to continue its work in the development, production and marketing of both well-established and new veterinary drugs, and nutritional additives (amino acids, vitamins, trace elements, etc.) for the Chinese market.
Hiru Corporation operates through its subsidiary, Jiangxi RongYu Pharmaceutical Group Inc., is a producer of Chinese herbs for the naturopathic industry in China. Jiangxi RongYu Pharmaceutical Group Co., Ltd. focuses on producing and manufacturing of herbs, herbal extracts and herbal preparations. HIRU's products are based on the traditional Chinese systems. HIRU researches and develops dosage approaches and health applications of these traditional recipes. On December 3, 2009, HIRU completed the merger with the China-based company Jiangxi RongYu Pharmaceutical Group Inc.
To learn more about HIRU visit: http://www.hirucorporation.com
Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM). Crown Equity Holdings Inc. (OTCPK:CRWE) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for (thirty) days of advertising for Hiru Corporation (OTCPK:HIRU).